RRM2 Monoklonaler Antikörper

RRM2 Monoklonal Antikörper für WB, IHC, IF/ICC, IP, ELISA

Wirt / Isotyp

Maus / IgG1

Getestete Reaktivität

human und mehr (1)

Anwendung

WB, IHC, IF/ICC, IP, CoIP, ELISA

Konjugation

Unkonjugiert

Publikationen(4)

CloneNo.

2A9A7

Kat-Nr. : 67006-1-Ig

Synonyme

RR2M, RR2, R2, EC:1.17.4.1, 2A9A7

---

• 

  WB analysis using 67006-1-Ig

  Various lysates were subjected to SDS PAGE followed by western blot with 67006-1-Ig (RRM2 antibody) at dilution of 1:20000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HEK-293 using 67006-1-Ig

  HEK-293 cells were subjected to SDS PAGE followed by western blot with 67006-1-Ig (RRM2 antibody) at dilution of 1:20000 incubated at room temperature for 1.5 hours.

• 

  IP experiment of HEK-293 using 67006-1-Ig

  IP result of anti-RRM2 (IP:67006-1-Ig, 4ug; Detection:67006-1-Ig 1:2000) with HEK-293 cells lysate 1470 ug.

• 

  IHC staining of human skin cancer using 67006-1-Ig

  Immunohistochemical analysis of paraffin-embedded skin cancer slide using 67006-1-Ig (RRM2 antibody) at dilution of 1:4000 (under 20x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IF Staining of HepG2 using 67006-1-Ig

  Immunofluorescent analysis of (-20°C Ethanol) fixed HepG2 cells using RRM2 antibody (67006-1-Ig, Clone: 2A9A7 ) at dilution of 1:400 and Multi-rAb CoraLite ® Plus 488-Goat Anti-Mouse Recombinant Secondary Antibody (H+L) (RGAM002).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: HeLa-Zellen, A431-Zellen, HEK-293-Zellen, Jurkat-Zellen, K-562-Zellen, MCF-7-Zellen, THP-1-Zellen
• Erfolgreiche IP: HEK-293-Zellen
• Erfolgreiche Detektion in IHC: humanes Hautkrebsgewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.
• Erfolgreiche Detektion in IF/ICC: HepG2-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:5000-1:50000
• Immunpräzipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunhistochemie (IHC): IHC : 1:2000-1:8000
• Immunfluoreszenz (IF)/ICC: IF/ICC : 1:200-1:800

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• WB: See 3 publications below
• IF: See 1 publications below
• CoIP: See 1 publications below

Produktinformation

67006-1-Ig bindet in WB, IHC, IF/ICC, IP, CoIP, ELISA RRM2 und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• In Publikationen genannte Reaktivität: human, Maus
• Wirt / Isotyp: Maus / IgG1
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: RRM2 fusion protein Ag28664
• Vollständiger Name: ribonucleotide reductase M2 polypeptide
• Berechnetes Molekulargewicht: 389 aa, 45 kDa
• Beobachtetes Molekulargewicht: 45 kDa
• GenBank-Zugangsnummer: BC030154
• Gene symbol: RRM2
• Gene ID (NCBI): 6241
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Protein-G-Reinigung
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Ribonucleotide reductase M2 subunit is one of two subunits that constitute ribonucleotide reductase, the enzyme that catalyzes the conversion of ribonucleotide 5'-diphosphates into 2'-deoxyribonucleotides, a rate-limiting step in the production of 2'-deoxyribonucleoside 5'-diphosphates (dNTP) required for DNA synthesis and repair that is required for DNA synthesis and repair [PMID:20825972, 19250552]. RRM2 is only expressed during the late G1/early S phase, and degraded in late S phase, and the activity of RNR, and therefore DNA synthesis and cell proliferation, is controlled during the cell cycle by the synthesis and degradation of RRM2 subunit [PMID:3894352].

Publikationen

Species	Application	Title
human	WB	Neoplasma; The SNHG16/miR-30a axis promotes breast cancer cell proliferation and invasion by regulating RRM2.; Authors - S M Du
human	WB,CoIP	Chem Biol Interact; Therapeutic Targeting of Thioredoxin Reductase 1 Causes Ferroptosis while Potentiating Anti-PD-1 Efficacy in Head and Neck Cancer; Authors - Ming-Shou Hsieh
human,mouse	WB	Mol Cell Biochem; FOXM1-activated IGF2BP3 promotes cell malignant phenotypes and M2 macrophage polarization in hepatocellular carcinoma by inhibiting ferroptosis via stabilizing RRM2 mRNA in an m6A-dependent manner; Authors - Heng Gao
human	IF	iScience; RRM2 promotes liver metastasis of pancreatic cancer by stabilizing YBX1 and activating the TGF-beta pathway; Authors - Zhouyuan Du